Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The endocrinological component and signaling pathways associated to cardiac hypertrophy

Full text
Cremasco Takano, Ana Paula [1] ; Senger, Nathalia [1] ; Barreto-Chaves, Maria Luiza M. [1]
Total Authors: 3
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Anat, Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Molecular and Cellular Endocrinology; v. 518, DEC 1 2020.
Web of Science Citations: 1

Although myocardial growth corresponds to an adaptive response to maintain cardiac contractile function, the cardiac hypertrophy is a condition that occurs in many cardiovascular diseases and typically precedes the onset of heart failure. Different endocrine factors such as thyroid hormones, insulin, insulin-like growth factor 1 (IGF-1), angiotensin II (Ang II), endothelin (ET-1), catecholamines, estrogen, among others represent important stimuli to cardiomyocyte hypertrophy. Thus, numerous endocrine disorders manifested as changes in the local environment or multiple organ systems are especially important in the context of progression from cardiac hypertrophy to heart failure. Based on that information, this review summarizes experimental findings regarding the influence of such hormones upon signalling pathways associated with cardiac hypertrophy. Understanding mechanisms through which hormones differentially regulate cardiac hypertrophy could open ways to obtain therapeutic approaches that contribute to prevent or delay the onset of heart failure related to endocrine diseases. (AU)

FAPESP's process: 19/06435-5 - Cellular and molecular mechanisms involved in cardiac aging: effects of cardiomyocyte-specific suppression of NF-kB
Grantee:Ana Paula Cremasco Takano
Support Opportunities: Regular Research Grants